From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Skinbiotherapeutics: can the boardroom greed of Sus Barbatus & the other directors be justified?

By Tom Winnifrith | Friday 1 December 2023

Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

I still think Skinbiotherapeutics (SBTX) shares are cheap after results which were snuck out after hours yesterday. However, I want to flag up that for a company with sales lower than that of my local CO-OP and which spunked c£3 million in each of the last two years, the boardroom pay is obscene and just cannot be justified. The worst offender is the Sus barbatus himself, CEO Stuart Ashman.
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.

Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was



Video: Poking Bears And Black Swans



Is Stuart Ashman lying again?



So farewell then

Time left: 08:05:59